TREACE MEDICAL CONCEPTS, INC. - 8-K Filing
Treace Medical Concepts reported Q1 2026 revenue of $47.2 million, a 10% decline from $52.6 million in the same period last year. The company recorded a net loss of $(18.0) million ($0.28 per share) and adjusted EBITDA of $(5.5) million for Q1 2026 compared to losses of $(15.9) million ($0.25 per share) and $(3.8) million, respectively, in the prior-year quarter. It reaffirmed full-year revenue guidance between $202 million and $212 million (a decline of 5%–0%) and expects a loss in adjusted EBITDA of $4.0 million to $6.0 million for 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $TMCI